Expression of gp130 in tumors and inflammatory disorders of the skin: Formal proof of its identity as CD146 (MUC18, Mel-CAM)

Journal of Investigative Dermatology

Volumn 125, Issue 2, 2005, Pages 353-363

  Schön, Margarete ^a   Kähne, Thilo ^b   Gollnick, Harald ^b   Schön, Michael P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

CD146; Inflammation; MUC18; Skin tumor; Tumor associated antigen

Indexed keywords

GLYCOPROTEIN GP 130; PROTEIN BCL 2; CD146 ANTIGEN; LEUKOCYTE ANTIGEN; MCAM PROTEIN, HUMAN; MEMBRANE PROTEIN; N ACETYLNEURAMINIC ACID; NERVE CELL ADHESION MOLECULE;

ARTICLE; BASAL CELL CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KERATINOCYTE; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SKIN BLOOD VESSEL; SKIN INFLAMMATION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; CELL CULTURE; CELL LINE; CYTOLOGY; DERMIS; EPIDERMIS; GLYCOSYLATION; METABOLISM; PEPTIDE MAPPING; PSORIASIS; SKIN ALLERGY; T CELL LYMPHOMA;

ANTIGENS, CD; ANTIGENS, CD146; BLOTTING, WESTERN; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TRANSFORMED; CELLS, CULTURED; DERMATITIS, ALLERGIC CONTACT; DERMIS; EPIDERMIS; GLYCOSYLATION; HUMANS; IMMUNOPRECIPITATION; KERATINOCYTES; LYMPHOMA, T-CELL; MEMBRANE GLYCOPROTEINS; N-ACETYLNEURAMINIC ACID; NEURAL CELL ADHESION MOLECULES; PEPTIDE MAPPING; PSORIASIS; SKIN NEOPLASMS;

EID: 24344488637     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23808.x     Document Type: Article

References (59)

1. Albino AP, Lloyd KO, Ikeda H, Old LJ: Biochemical analysis of a 130,000 molecular weight glycoprotein on human melanoma cells. J Immunol 131:1595-1599, 1983
2. Bardin N, Frances V, Lesaule G, Horschowski N, George F, Sampol J: Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 218:210-216, 1996a
3. Bardin N, George F, Mutin M, et al: S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens 48:531-539, 1996b
4. Bean MA, Bloom BR, Herberman RB, Old LJ, Oettgen HF, Klein G, Terry WD: Cell-mediated cytotoxicity for bladder carcinoma: Evaluation of a workshop. Cancer Res 35:2902-2913, 1975
5. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-771, 1988
6. Bruggen J, Macher E, Sorg C: Expression of surface antigens and its relation to parameters of malignancy in human malignant melanoma. Cancer Immunol Immunother 10:121-127, 1981
7. Delehedde M, Cho SH, Sarkiss M, Brisbay S, Davies M, El-Naggar AK, McDonnell TJ: Altered expression of bcl-2 family member proteins in non-melanoma skin cancer. Cancer 85:1514-1522, 1999
8. Dippold WG, Lloyd KO, Li LT, Ikeda H, Oettgen HF, Old LJ: Cell surface antigens of human malignant melanoma: Definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA 77:6114-6118, 1980
9. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP: In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51:1417-1423, 1973
10. Guevara-Patino JA, Turk MJ, Wolchok JD, Houghton AN: Immunity to cancer through immune recognition of altered self: Studies with malignant melanoma. Adv Cancer Res 90:157-177, 2003
11. Hampel H, Korschenhausen DA, Schwarz MJ, et al: Detection of the novel cell adhesion molecule MUC18 in human brain tissue. Neuroimmunomodulation 4:57-61, 1997
12. Holzmann B, Lehmann JM, Ziegler-Heitbrock HW, Funke I, Riethmüller G, Johnson JP: Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen. Int J Cancer 41:542-547, 1988
13. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ: Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 156:1755-1766, 1982
14. Johnson JP, Bar-Eli M, Jansen B, Markhof E: Melanoma progression- associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer 73:769-774, 1997
15. Johnson JP, Lehmann JM, Stade BG, Rothbacher U, Sers C, Riethmüller G: Functional aspects of three molecules associated with metastasis development in human malignant melanoma. Invasion Metastasis 9: 338-350, 1989
16. Johnson JP, Rummel MM, Rothbacher U, Sers C: MUC18: A cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Curr Top Microbiol Immunol 213 (Pt 1):95-105, 1996
17. Klein CE, Ozer HL, Traganos F, Atzpodien J, Oettgen HF, Old LJ: A transformation-associated 130-kD cell surface glycoprotein is growth controlled in normal human cells. J Exp Med 167:1684-1696, 1988
18. Kocak M, Bozdogan O, Erkek E, Atasoy P, Birol A: Examination of Bcl-2, Bcl-X and bax protein expression in psoriasis. Int J Dermatol 42:789-793, 2003
19. Kuroki M, Shibaguchi H, Imakiire T, et al: Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. Anticancer Res 23:4377-4381, 2003
20. Kuroki M, Ueno A, Matsumoto A, et al: Significance of tumor-associated antigens in the diagnosis and therapy of cancer: An overview. Anticancer Res 22:4255-4264, 2002
21. Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmüller G, Johnson JP: Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47:841-845, 1987
22. Lehmann JM, Riethmüller G, Johnson JP: MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86:9891-9895, 1989
23. McGary EC, Heimberger A, Mills L, et al: A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res 9:6560-6566, 2003
24. Mills L, Tellez C, Huang S, et al: Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62: 5106-5114, 2002
25. Morales-Ducret CR, van de Rijn M, LeBrun DP, Smoller BR: Bcl-2 expression in primary malignancies of the skin. Arch Dermatol 131:909-912, 1995
26. Müller-Wieprecht V, Riebeling C, Stooss A, Orfanos CE, Geilen CC: Bcl-2 transfected HaCaT keratinocytes resist apoptotic signals of ceramides, tumor necrosis factor alpha, and 1-alpha, 25-dihydroxyvitamin D(3). Arch Dermatol Res 292:455-462, 2000
27. Öhman Forslund K, Nordqvist K: The melanoma antigen genes-any clues to their functions in normal tissues? Exp Cell Res 265:185-194, 2001
28. Pickl WF, Majdic O, Fischer GF, et al: MUC18/MCAM (CD146), an activation antigen of human T lymphocyte. J Immunol 158:2107-2115, 1997
29. Ramdial PK, Madaree A, Reddy R, Chetty R: Bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol 27:283-291, 2000
30. Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ: Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 45: 4401-4411, 1985
31. Rogers SJ, Harrington KJ, Eccles SA, Nutting CM: Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. Expert Rev Anticancer Ther 4:569-583, 2004
32. Ross JS, Fletcher JA, Bloom KJ, et al: Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell Proteomics 3:379-398, 2004
33. Ross JS, Gray GS: Targeted therapy for cancer: The HER-2/neu and Herceptin story. Clin Leadersh Manag Rev 17:333-340, 2003
34. Rummel MM, Sers G, Johnson JP: Phorbol ester and cyclic AMP-mediated regulation of the melanoma-associated cell adhesion molecule MUC18/MCAM. Cancer Res 56:2218-2223, 1996
35. Salgaller ML: Technology evaluation: Bevacizumab, Genentech/Roche. Curr Opin Mol Ther 5:657-667, 2003
36. Schmidt KV, Wood BA: Trends in cancer therapy: Role of monoclonal antibodies. Semin Oncol Nurs 19:169-179, 2003
37. Schön M, Bong AB, Drewniok C, et al: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95:1138-1149, 2003
38. Schön M, Klein CE, Hogenkamp V, Kaufmann R, Wienrich BG, Schön MP: Basal-cell adhesion molecule (B-CAM) is induced in epithelial skin tumors and inflammatory epidermis, and is expressed at cell-cell and cell-substrate contact sites. J Invest Dermatol 115:1047-1053, 2000
39. Schön MP, Limat A, Hartmann B, Klein CE: Characterization of an 80-kD membrane glycoprotein (gp80) of human keratinocytes: A marker for commitment to terminal differentiation in vivo and in vitro. J Invest Dermatol 105:418-425, 1995
40. Schön MP, Orfanos CE: Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T-16 antigen (Trop-2, MOv-16). Int J Cancer 60:88-92, 1995
41. Schön MP, Schön M, Mattes MJ, Stein R, Weber L, Alberti S, Klein CE: Biochemical and immunological characterization of the human carcinoma-associated antigen MH99/KS1/4. Int J Cancer 55:988-995, 1993
42. Schön MP, Wienrich BG, Drewniok C, et al: Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 122:1266-1276, 2004
43. Schwarz MJ, Müller N, Korschenhausen D, et al: Melanoma-associated adhesion molecule MUC18/MCAM (CD146) and transcriptional regulator mader in normal human CNS. Neuroimmunomodulation 5:270-276, 1998
44. Sers C, Kirsch K, Rothbacher U, Riethmüller G, Johnson JP: Genomic organization of the melanoma-associated glycoprotein MUC18: Implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci USA 90:8514-8518, 1993
45. Shevchenko A, Wilm M, Vorm O, Mann M: Mass spectrometric sequencing of proteins from silver stained polyacrylamide gels. Anal Chem 68:850-858, 1996
46. Shih IM: The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 189: 4-11, 1999
47. Shih IM, Elder DE, Hsu MY, Herlyn M: Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 145:837-845, 1994a
48. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M: Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 54:2514-2520, 1994b
49. Shih IM, Nesbit M, Herlyn M, Kurman RJ: A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol 11:1098-1106, 1998
50. Shih IM, Speicher D, Hsu MY, Levine E, Herlyn M: Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res 57:3835-3840, 1997
51. Staibano S, Lo Muzio L, Pannone G, et al: Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck. Anticancer Res 21:3757-3764, 2001
52. Suminami Y, Nawata S, Kato H: Biological role of SCC antigen. Tumour Biol 19:488-493, 1998
53. Um JH, Kwon JK, Kang CD, et al: Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J Pharmacol Exp Ther 311:1062-1070, 2004
54. Weninger W, Rendl M, Mildner M, et al: Keratinocytes express the CD146 (Muc18/S-endo) antigen in tissue culture and during inflammatory skin diseases. J Invest Dermatol 115:219-224, 2000
55. Wikonkal NM, Berg RJ, van Haselen CW, et al: Bcl-2 vs p 53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch Dermatol 133:599-602, 1997
56. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
57. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, Bar-Eli M: Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57:2295-2303, 1997a
58. Xie S, Price JE, Luca M, Jean D, Ronai Z, Bar-Eli M: Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 15:2069-2075, 1997b
59. Zhang JY: Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detect Prevent 28:114-118, 2004